Description

Entecavir Capsules (Hui’erDing) 0.2?g are synthetic nucleoside analog antiviral capsules designed to inhibit hepatitis B virus replication. Entecavir acts by blocking multiple steps of HBV DNA synthesis via inhibition of reverse transcriptase and polymerase functions. Originally developed to treat chronic hepatitis B infection, it has been studied extensively in research models for antiviral mechanisms, viral resistance studies, and combination therapies. Manufactured under Chinese licence H20210035 by Hebei Medical University Pharmaceutical Factory. Each box contains seven capsules. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Entecavir Capsules (Hui’erDing) provide entecavir, a deoxyguanosine analog that competes with natural nucleotides to inhibit HBV reverse transcriptase. It blocks viral DNA base priming, negative-strand synthesis, and positive-strand synthesis, effectively halting HBV replication. In research, Entecavir Capsules (Hui’erDing) are utilized to study antiviral efficacy, viral resistance mutation emergence, and combination antiviral therapies, especially in chronic hepatitis B infection models. Suitable for immune modulation and virology research contexts. Strictly for laboratory use.

Side Effects (For Reference Only in Models)

In experimental models, potential side effects may include mild fatigue, headache, nausea, elevated liver enzyme markers, and kidney function changes. Rare lab models may show signs of mild liver enlargement or transient lactic acid increase. These effects depend on dose and duration, and should inform safety design in research protocols.

Disclaimer

Entecavir Capsules (Hui’erDing) 0.2?g are intended exclusively for laboratory research use. Not for human or veterinary therapeutic use.